The risk of rhabdomyolysis in patients using statins increases with the concurrent use of CYP3A4 inhibitors such as antifungal agents (itraconazole, ketoconazole, and fluconazole) or macrolide antibiotics (erythromycin and clarithromycin) [39]. This evidence concerns the gene CYP3A4 and rhabdomyolysis.